Equity Method Investments (Details) - USD ($)	6 Months Ended	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019	Jul. 31, 2019
Schedule Of Equity Method Investments [Line Items]
Revenue recognized		$ 18,600,000	$ 18,700,000
Contract liabilities		740,500,000	45,100,000
Net loss		(191,000,000.0)	(119,300,000)	$ (70,300,000)
Loss from equity method investment		0	0	(24,700,000)
Equity method investments		0
Oerth
Schedule Of Equity Method Investments [Line Items]
Cash commitment		$ 49,400,000			$ 49,400,000
Ownership interest in joint venture, percentage		50.00%			50.00%
Future grant of incentive units to service providers, percentage					15.00%
Revenue recognized		$ 24,700,000
Contract liabilities		24,700,000			$ 24,700,000
Research and development expenses				49,400,000
Loss from equity method investment		0	0	24,700,000
Equity method investments	$ 0			0
Oerth | Equity Method Investment, Nonconsolidated Investee or Group of Investees
Schedule Of Equity Method Investments [Line Items]
Operating expenses		14,300,000	8,300,000	49,800,000
Net loss		$ 14,300,000	$ 8,300,000	$ 49,800,000
Bayer LP | Oerth
Schedule Of Equity Method Investments [Line Items]
Cash commitment					$ 56,000,000
Contributed to joint venture entity	$ 16,000,000
Ownership interest in joint venture, percentage		50.00%			50.00%